explore -WSS

explore

author：leisure time 2025-09-29 01:29:40 - browse：3

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Readout Newsletter: Parkinson's study, Gilead, CG Oncology

WSS

Immunocompromised patients offer clues on chronic Covid

Microsoft launches AI tool for clinical documentation through Epic

Mass General, Mayo Clinic look to monetize custom

Cassava reveals details — and problems — with Alzheimer's study

Why Sanofi got shellacked over its spinoff

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Wikipedia

explore

knowledge

How one medical school became remarkably diverse

Microsoft launches AI tool for clinical documentation through Epic

Hollywood unions extend contract negotiations for actors

Medicare bonuses could stop drug shortages under Senate plan

Guidelines to prevent youth baseball injuries need more muscle

The FDA weighs the risks of candy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Diversifying clinical trials isn't enough to close racial gaps: study

BioMarin wins approval for gene therapy to treat hemophilia A

Mass General, Mayo Clinic look to monetize custom

knowledge

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

The FDA weighs the risks of candy

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: What happened with Sarepta's Duchenne data

Maker of FluMist seeks to allow at

HPV vaccine, cervical cancer study delivers historic results

hotspot

focus

entertainment

leisure time